ITCI Intra-Cellular Therapies Inc

Price (delayed)

$74.54

Market cap

$7.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.46

Enterprise value

$7.08B

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this ...

Highlights
The gross profit has soared by 87% YoY and by 10% from the previous quarter
The revenue has soared by 86% YoY and by 11% from the previous quarter
ITCI's quick ratio is down by 38% YoY and by 14% from the previous quarter
The equity has declined by 10% year-on-year

Key stats

What are the main financial stats of ITCI
Market
Shares outstanding
96.81M
Market cap
$7.22B
Enterprise value
$7.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.13
Price to sales (P/S)
15.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.25
Earnings
Revenue
$464.37M
EBIT
-$139.04M
EBITDA
-$138.51M
Free cash flow
-$124.47M
Per share
EPS
-$1.46
Free cash flow per share
-$1.3
Book value per share
$6.15
Revenue per share
$4.84
TBVPS
$7.6
Balance sheet
Total assets
$728.3M
Total liabilities
$136.87M
Debt
$16.94M
Equity
$591.42M
Working capital
$544.25M
Liquidity
Debt to equity
0.03
Current ratio
5.41
Quick ratio
4.97
Net debt/EBITDA
0.96
Margins
EBITDA margin
-29.8%
Gross margin
92.7%
Net margin
-30.1%
Operating margin
-34.3%
Efficiency
Return on assets
-19.4%
Return on equity
-23%
Return on invested capital
-26.7%
Return on capital employed
-23%
Return on sales
-29.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITCI stock price

How has the Intra-Cellular Therapies stock price performed over time
Intraday
3%
1 week
15.1%
1 month
8%
1 year
19.24%
YTD
4.08%
QTD
7.72%

Financial performance

How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$464.37M
Gross profit
$430.63M
Operating income
-$159.38M
Net income
-$139.67M
Gross margin
92.7%
Net margin
-30.1%
The gross profit has soared by 87% YoY and by 10% from the previous quarter
The revenue has soared by 86% YoY and by 11% from the previous quarter
The net margin has surged by 71% year-on-year and by 18% since the previous quarter
The operating margin has soared by 67% YoY and by 17% from the previous quarter

Growth

What is Intra-Cellular Therapies's growth rate over time

Valuation

What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
12.13
P/S
15.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.25
The EPS has grown by 46% YoY and by 10% from the previous quarter
ITCI's P/B is 90% above its 5-year quarterly average of 6.4 and 26% above its last 4 quarters average of 9.6
The equity has declined by 10% year-on-year
The stock's price to sales (P/S) is 99% less than its 5-year quarterly average of 1962.6 but 2.6% more than its last 4 quarters average of 15.0
The revenue has soared by 86% YoY and by 11% from the previous quarter

Efficiency

How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 71% YoY and by 19% from the previous quarter
Intra-Cellular Therapies's ROA has increased by 39% YoY and by 9% from the previous quarter
The ROE has grown by 36% YoY and by 8% from the previous quarter
ITCI's return on invested capital is up by 34% year-on-year and by 7% since the previous quarter

Dividends

What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITCI.

Financial health

How did Intra-Cellular Therapies financials performed over time
The company's current ratio fell by 39% YoY and by 21% QoQ
The total liabilities has increased by 39% YoY and by 17% from the previous quarter
The debt is 97% smaller than the equity
The debt has declined by 15% year-on-year and by 3.1% since the previous quarter
The equity has declined by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.